Shortcomings and future perspectives of antiviral drugs in Covid-19

A video interview with a researcher expert in respiratory viruses features the state-of-the-art of antiviral research and the work to improve their efficacy

Published on

30 Nov 2022

Category

Press releases

Antiviral drugs are one of the currently available tools to reduce the complications of Covid-19 infections, as they act by blocking the mechanisms of virus reproduction.

We asked Valeria Cagno, Group Leader at the Institute of Microbiology of the University of Lausanne (Switzerland) and the University Hospital of Lausanne, to shed some light on this topic and to explain which antiviral drugs are currently available, what the current problems are, and what the future use and perspectives can be.

One of the limitations she mentions is the absence of a broad-spectrum antiviral.

“When we have a bacterial infection, we do not have to know which is the bacteria that is infecting us and we just take a broad-spectrum antibiotic. This doesn’t exist for viruses” she said.

That’s why, in her lab, she is searching for innovative antiviral strategies for respiratory viruses.

The video interview is available here

Share this news:
Published on

30 Nov 2022

Category

Press releases

Related updates

Results

See all >

Elimination of Carryover Contamination in Real-Time Reverse Transcriptase Loop-Mediated Isothermal Amplification for Rapid Detection of the SARS-CoV-2 Virus in Point-of-Care Testing

Scientific publications — 20 Apr 2022

Loop-mediated isothermal amplification (LAMP) is being used as a robust rapid diagnostic tool to prevent the transmission of infectious diseases. However, carryover contamination of LAMP-amplified products originating from previous tests has been a problem in LAMP-based bio-analytical assays. In this study, we developed a Cod-uracil-DNA-glycosylase real-time reverse transcriptase LAMP assay (Cod-UNG-rRT-LAMP) for the elimination of...